Table 8. 1-, 3-, and 5-year overall and tumor-free survival rate comparison according to the BCLC staging system.

	1-, 3-, and 5-year overall survival rate (%)			P value	1-, 3-, and 5-year tumor-free survival rate (%)			P value
	1-year	3-year	5-year		1-year	3-year	5-year
BCLC-A, solitary RFA (84)	92.9%	82.1%	67.9%	0.953	86.9%	71.4%	58.3%	0.388
BCLC-A, TACE combined with RFA (46)	93.5%	80.4%	67.4%		84.8%	67.4%	50.0%
BCLC-B, solitary RFA (79)	89.9%	75.9%	53.2%	0.987	78.5%	53.2%	35.4%	0.912
BCLC-B, TACE combined with RFA (35)	88.6%	74.3%	54.3%		74.3%	54.3%	37.1%
RFA, BCLC-A (130)	93.1%	81.5%	67.7%	0.032*	86.2%	70%	55.4%	0.002*
RFA, BCLC-B (114)	89.5%	75.4%	53.5%		77.2%	53.5%	36.0%
BCLC-A, solitary resection (372)	93.0%	82.8%	69.4%	0.536	83.9%	63.4%	58.1%	0.853
BCLC-A, TACE combined with resection (158)	92.3%	81.0%	70.9%		84.8%	69.0%	60.8%
BCLC-B, solitary resection (261)	91.2%	79.7%	62.5%	0.933	80.8%	62.5%	52.1%	0.955
BCLC-B, TACE combined Resection (110)	92.7%	75.5%	62.7%		84.5%	62.7%	50.0%
Resection, BCLC-A (530)	92.8%	82.3%	69.8%	0.031	84.2%	65.1%	58.9%	0.045*
Resection, BCLC-B (371)	91.6%	78.4%	62.5%		81.9%	62.5%	51.5%
BCLC-A, solitary LT (181)	92.8%	82.9%	74.0%	0.978	87.3%	77.3%	68.6%	0.937
BCLC-A, TACE combined with LT (46)	93.5%	80.4%	73.9%		89.1%	76.1%	67.4%
BCLC-B, solitary LT (156)	90.4%	75.0%	62.2%	0.937	82.7%	62.2%	54.5%	0.528
BCLC-B, TACE combined with LT (32)	90.6%	75.0%	62.5%		84.4%	62.5%	50.0%
LT, BCLC-A (227)	93.0%	82.4%	74.0%	0.010*	87.7%	77.1%	68.3%	0.002*
LT, BCLC-B (188)	90.4%	75.0%	62.2%		83.0%	62.2%	53.7%

BCLC: Barcelona Clinic Liver Cancer; TACE: transarterial chemoembolization; RFA: Radiofrequency ablation; LT: liver transplantation.